Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04940039
Other study ID # CR108924
Secondary ID R092670PSY4002
Status Completed
Phase Phase 4
First received
Last updated
Start date July 22, 2021
Est. completion date April 16, 2024

Study information

Verified date May 2024
Source Janssen-Cilag International NV
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the long-term symptomatic response (Visit 2 [Week 1] to Visit 14/Week 66 [End of Study {EOS}]) measured by change in the Clinical Global Impressions -Severity for Schizophrenia (CGI-SS) in participants with schizophrenia who are treated in Rwandan real-world healthcare settings with the antipsychotic regimen that starts with oral anti-psychotic (AP) formulation followed by continued treatment with (paliperidone palmitate 1-month [PP1M] and 3-month [PP3M] formulations).


Recruitment information / eligibility

Status Completed
Enrollment 93
Est. completion date April 16, 2024
Est. primary completion date April 16, 2024
Accepts healthy volunteers No
Gender All
Age group 19 Years to 34 Years
Eligibility Inclusion Criteria: - Diagnosis of schizophrenia by Mini International Neuropsychiatric Interview (MINI)-Screen / MINI (Module K) that requires treatment initiation or a change in treatment to better address safety, efficacy, or adherence limitations of current treatment - Eligible for treatment in the Rwandan mental healthcare system - At least moderately ill as measured by the Clinical Global Impression - Severity of Schizophrenia (CGI-SS) scale for schizophrenia (rating of greater than or equal to [>=] 4). This criterion needs to be re-confirmed at Visit 2 - Has a primary caregiver who is willing to participate in this study (caregiver should be knowledgeable about the participant's condition, provide economic/cost of care information, and is expected to be with the participant for greater than [>] 24 hours each week for the duration of the study) - A woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) during screening - Able to give consent to participate in a clinical study that includes treatment with risperidone and long-acting injectable (LAI) formulations of paliperidone palmitate. Participants must be willing to receive injections. The participant and the caregiver must sign their own informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study Exclusion Criteria: - Has a physical, mental, or legal incapacity that prevents a valid consent or capacity to complete about 12 months of treatment with antipsychotic medication and compliance with this study protocol - History of organic brain syndromes, comorbid psychiatric and/or physical illnesses, or significant comorbid substance abuse that is likely to interfere with understanding of or compliance with study requirements - Known allergies, hypersensitivity, or intolerance to risperidone or paliperidone palmitate or its excipients - Received an investigational intervention including investigational vaccines or used an invasive investigational medical device within 30 days before the planned first dose of study intervention, or is currently enrolled in an investigational study - Pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study intervention - Poor prior response to risperidone or paliperidone

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Risperidone 3 mg
Participants will receive 3 mg oral risperidone tablet once daily for 3 days.
Paliperidone Palmitate 50 mg eq.
Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks).
Paliperidone Palmitate 75 mg eq.
Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks.
Paliperidone Palmitate 100 mg eq.
Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks.
Paliperidone Palmitate 150 mg eq.
Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks.
Paliperidone Palmitate 175 mg eq.
Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks.
Paliperidone Palmitate 263 mg eq.
Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks.
Paliperidone Palmitate 350 mg eq.
Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks.
Paliperidone Palmitate 525 mg eq.
Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks.

Locations

Country Name City State
Rwanda University Teaching Hospital of Butare(CHUB) Butare
Rwanda Kibuye Referral Hospital Kibuye
Rwanda CARAES Ndera Neuro-Psychiatric Hospital Kigali
Rwanda University Teaching Hospital of Kigali Kigali
Rwanda Rwamagana Provincial Hospital Rwamagana

Sponsors (1)

Lead Sponsor Collaborator
Janssen-Cilag International NV

Country where clinical trial is conducted

Rwanda, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Change in Clinical Global Impression Severity of Schizophrenia (CGI-SS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [End of Study {EOS}]) The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms). Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Secondary Mean Change in CGI-SS Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS]) The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms). Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Secondary Mean Change in CGI-SS Score from Visit 2 (Week 1) to Visit 6 (Week 25) The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms). Visit 2 (Week 1) to Visit 6 (Week 25)
Secondary Change in Personal and Social Performance (PSP) Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS]) The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area. Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Secondary Change in PSP Scale Scores from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS]) The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area. Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Secondary Change in PSP Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25) The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area. Visit 2 (Week 1) to Visit 6 (Week 25)
Secondary Change in Patient Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS]) The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction. Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Secondary Change in Patient Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS]) The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction. Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Secondary Change in Patient Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25) The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction. Visit 2 (Week 1) to Visit 6 (Week 25)
Secondary Change in Clinician Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS]) The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction. Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Secondary Change in Clinician Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS]) The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction. Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Secondary Change in Clinician Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25) The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction. Visit 2 (Week 1) to Visit 6 (Week 25)
Secondary Change in Schizophrenia Quality of Life Scale (SQLS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS]) The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life. Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Secondary Change in SQLS Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS]) The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life. Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Secondary Change in SQLS Score from Visit 2 (Week 1) to Visit 6 (Week 25) The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life. Visit 2 (Week 1) to Visit 6 (Week 25)
Secondary Number of Participants with Treatment-emergent Adverse Events An adverse event is any untoward medical occurrence in a clinical study participants administered a medicinal (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the intervention. Treatment-emergent adverse events are adverse events with onset after the initiation of treatment in observation phase and separately for initiation of paliperidone palmitate (PP) in Lead-in phase or that are a consequence of a pre-existing condition that has worsened after each treatment phase starts. Up to Week 66
Secondary Number of Participants with Abnormalities in Clinical Laboratory Measures Number of participants with abnormalities in clinical laboratory measures (including serum chemistry, hematology and urinalysis) will be reported. Up to Week 66
Secondary Number of Participants with Abnormalities in Vital Signs Number of participants with abnormalities in vital signs (temperature [oral], pulse/heart rate, and blood pressure) will be reported. Up to Week 66
Secondary Number of Participants with Abnormalities in Electrocardiogram (ECG) Number of participants with abnormalities in ECG will be reported. Up to Week 66
Secondary Number of Participants with Abnormalities in Physical Examination Number of participants with abnormalities in physical examination (including body weight, waist circumference, and height) will be reported. Up to Week 66
Secondary Number of Participants With Pregnancy Outcome as a Safety Measure Number of participants with pregnancy outcome will be reported. Up to Week 66
Secondary Number of Participants With Suicidal Ideation and Behavior as Assessed by Columbia Suicide Severity Rating Scale (C-SSRS) Score C-SSRS is an approved and standardized scale for the assessment of the severity of suicidality, through clinical interview. The maximum score assigned for each participant will be summarized into one of three categories: no suicidal ideation or behavior (0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranges from 1 to 10. Higher scores indicate greater severity. Number of participants with suicidal ideation and behavior will be reported. Visit 12 (Week 46) to Visit 14 (Week 66 [EOS])
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A